MyFinsight
Home
Blog
About
Proceeds from
financing-June Financing
$162,073K
Proceeds from
at-the-market offerings, net...
$29,331K
Proceeds from stock
option exercises
$1,534K
Proceeds from espp
issuances
$585K
Net cash provided by
financing activities
$193,523K
(1.53%↑ Y/Y)
Net increase in cash
and cash...
$52,165K
(-65.58%↓ Y/Y)
Canceled cashflow
$141,358K
Proceeds from
sales/maturities of investments
$44,691K
Stock-based compensation
$13,606K
(115.35%↑ Y/Y)
Accounts payable
$2,100K
(-57.47%↓ Y/Y)
Accrued expenses and
other current...
$84K
(-97.06%↓ Y/Y)
Non-cash lease expense
$25K
(-66.22%↓ Y/Y)
Depreciation expense
$9K
(80.00%↑ Y/Y)
Net cash used in
investing activities
-$97,632K
(-71688.24%↓ Y/Y)
Net cash used in
operating activities
-$43,656K
(-12.18%↓ Y/Y)
Effect of exchange
rates on cash and cash...
-$70K
Canceled cashflow
$44,691K
Canceled cashflow
$15,824K
Purchases of investments
$142,323K
Net loss
-$55,765K
(20.68%↑ Y/Y)
Prepaid expenses and
other current assets
$2,832K
(108.54%↑ Y/Y)
Related party accrued
expenses and other...
-$495K
(84.15%↑ Y/Y)
Accretion/amortization on investments
$358K
Operating lease
liabilities
-$30K
Back
Back
Cash Flow
Jade Biosciences, Inc. (JBIO)
Jade Biosciences, Inc. (JBIO)
source: myfinsight.com